schliessen

Filtern

 

Bibliotheken

On-Treatment Analysis of the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT)

Abstract Background We aimed to determine the efficacy and safety of adding ezetimibe (Ez) to simvastatin (S) in a post-acute coronary syndrome (ACS) population in a prespecified on-treatment analysis. Methods We evaluated 17,706 post-ACS patients from the IMPROVE-IT trial who had low-density lipopr... Full description

Journal Title: The American heart journal 2016, Vol.182, p.89-96
Main Author: Blazing, Michael A., MD
Other Authors: Giugliano, Robert P., MD, SM , de Lemos, James A., MD , Cannon, Christopher P., MD , Tonkin, Andrew, MBBS, MD , Ballantyne, Christie M., MD , Lewis, Basil S., MD , Musliner, Thomas A., MD , Tershakovec, Andrew M., MD, MPH , Lokhnygina, Yuliya, PhD , White, Jennifer A., MS , Reist, Craig, PhD , McCagg, Amy, BS , Braunwald, Eugene, MD
Format: Electronic Article Electronic Article
Language: English
Subjects:
Quelle: Alma/SFX Local Collection
Publisher: United States: Elsevier Inc
ID: ISSN: 0002-8703
Link: https://www.ncbi.nlm.nih.gov/pubmed/27914504
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: cdi_proquest_miscellaneous_1868340905
title: On-Treatment Analysis of the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT)
format: Article
creator:
  • Blazing, Michael A., MD
  • Giugliano, Robert P., MD, SM
  • de Lemos, James A., MD
  • Cannon, Christopher P., MD
  • Tonkin, Andrew, MBBS, MD
  • Ballantyne, Christie M., MD
  • Lewis, Basil S., MD
  • Musliner, Thomas A., MD
  • Tershakovec, Andrew M., MD, MPH
  • Lokhnygina, Yuliya, PhD
  • White, Jennifer A., MS
  • Reist, Craig, PhD
  • McCagg, Amy, BS
  • Braunwald, Eugene, MD
subjects:
  • Abridged Index Medicus
  • Acute Coronary Syndrome - blood
  • Acute Coronary Syndrome - diagnosis
  • Acute Coronary Syndrome - drug therapy
  • Aged
  • Analysis
  • Anticholesteremic Agents - administration & dosage
  • Anticholesteremic Agents - adverse effects
  • Cardiovascular
  • Cardiovascular disease
  • Cholesterol, LDL - blood
  • Clinical trials
  • Coronary heart disease
  • Dose-Response Relationship, Drug
  • Drug Monitoring - methods
  • Drug Synergism
  • Drug Therapy, Combination - methods
  • Drug Therapy, Combination - statistics & numerical data
  • Ezetimibe - administration & dosage
  • Ezetimibe - adverse effects
  • Female
  • Health risk assessment
  • Humans
  • Low density lipoprotein
  • Male
  • Middle Aged
  • Mortality
  • Simvastatin
  • Simvastatin - administration & dosage
  • Simvastatin - adverse effects
  • Treatment Outcome
ispartof: The American heart journal, 2016, Vol.182, p.89-96
description: Abstract Background We aimed to determine the efficacy and safety of adding ezetimibe (Ez) to simvastatin (S) in a post-acute coronary syndrome (ACS) population in a prespecified on-treatment analysis. Methods We evaluated 17,706 post-ACS patients from the IMPROVE-IT trial who had low-density lipoprotein cholesterol (LDL-C) values between 50 and 125 mg/dL and who received Ez 10 mg/day with S 40 mg/day (Ez/S) or placebo with simvastatin 40 mg/day (P/S). The primary composite endpoint was cardiovascular death, myocardial infarction, unstable angina, coronary revascularization ≥30 days post randomization, or stroke. The on-treatment analysis included patients who received study drug for the duration of the trial or experienced a primary endpoint or non-cardiovascular death within 30 days of drug discontinuation. Results Mean LDL-C values at 1 year were 71 mg/dL for P/S and 54 mg/dL for Ez/S (absolute difference− 17 mg/dL = −24%; P < .001). The 7-year Kaplan–Meier estimate of the primary endpoint occurred in 32.4% in the P/S arm and 29.8% in the Ez/S arm (absolute difference 2.6%; HRadj 0.92 [95% CI 0.87–0.98]; P = .01). The absolute treatment effect favoring Ez/S was 30% greater than in the intention-to-treat analysis of IMPROVE-IT. Conclusions This analysis provides additional support for the efficacy and safety of adding Ez to S in this high-risk, post-ACS population.
language: eng
source: Alma/SFX Local Collection
identifier: ISSN: 0002-8703
fulltext: fulltext
issn:
  • 0002-8703
  • 1097-6744
url: Link


@attributes
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
RANK2.5259044
LOCALfalse
PrimoNMBib
record
control
sourceidgale_proqu
recordidTN_cdi_proquest_miscellaneous_1868340905
sourceformatXML
sourcesystemPC
galeidA476964168
sourcerecordidA476964168
originalsourceidFETCH-LOGICAL-c550t-d42a3b34c7ce87a68e2f1bbaeb87460c62697bbd122b24a158332ec22075095c3
addsrcrecordideNqNkl2L1DAYhYso7jj6A7yRgjfrRWuSpkmrIAzLqAMrI-u4tyFN37oZ22RM0oX596aOuuuwLBJI2uQ5583HSZLnGOUYYfZ6m8urbU7iZ47qHCH6IJlhVPOMcUofJjOEEMkqjoqT5In32_jLSMUeJyeE15iWiM4SszbZxoEMA5iQLozs91771HZpuIJ0NeycvYY2vYB2VEFbM62sx6DsAP5NerkP1mmTLrtOK6n26coEcEZOpOzTjdOxP119-nyxvlxmq82rp8mjTvYenv0e58nX98vN2cfsfP1hdbY4z1RZopC1lMiiKajiCiouWQWkw00joak4ZUgxwmreNC0mpCFU4rIqCgKKEMRLVJeqmCenB9-4_x8j-CAG7RX0vTRgRy9wxaqCohqV_4HGioTiuojoyyN0a8d43P5A8aJk5Bb1TfYgtOlscFJNpmJBOasZxbH4PMnvoGJrYdDKGuh0nP9H8OIOgbgN4AOgnPXeQSd2Tg_S7QVGYsqL2IqYFzHlRaBaxLzcmO7GZoD2r-JPQCLAj0yVDr_eN1bX_b3Wbw9KiO98rcEJrzQYBa12oIJorb5X_e5IrXptYsj677AHf3PvwhOBxJcp6lPSMSsQruuy-AlyTvHu
sourcetypeAggregation Database
isCDItrue
recordtypearticle
pqid1846735623
display
typearticle
titleOn-Treatment Analysis of the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT)
sourceAlma/SFX Local Collection
creatorBlazing, Michael A., MD ; Giugliano, Robert P., MD, SM ; de Lemos, James A., MD ; Cannon, Christopher P., MD ; Tonkin, Andrew, MBBS, MD ; Ballantyne, Christie M., MD ; Lewis, Basil S., MD ; Musliner, Thomas A., MD ; Tershakovec, Andrew M., MD, MPH ; Lokhnygina, Yuliya, PhD ; White, Jennifer A., MS ; Reist, Craig, PhD ; McCagg, Amy, BS ; Braunwald, Eugene, MD
creatorcontribBlazing, Michael A., MD ; Giugliano, Robert P., MD, SM ; de Lemos, James A., MD ; Cannon, Christopher P., MD ; Tonkin, Andrew, MBBS, MD ; Ballantyne, Christie M., MD ; Lewis, Basil S., MD ; Musliner, Thomas A., MD ; Tershakovec, Andrew M., MD, MPH ; Lokhnygina, Yuliya, PhD ; White, Jennifer A., MS ; Reist, Craig, PhD ; McCagg, Amy, BS ; Braunwald, Eugene, MD
descriptionAbstract Background We aimed to determine the efficacy and safety of adding ezetimibe (Ez) to simvastatin (S) in a post-acute coronary syndrome (ACS) population in a prespecified on-treatment analysis. Methods We evaluated 17,706 post-ACS patients from the IMPROVE-IT trial who had low-density lipoprotein cholesterol (LDL-C) values between 50 and 125 mg/dL and who received Ez 10 mg/day with S 40 mg/day (Ez/S) or placebo with simvastatin 40 mg/day (P/S). The primary composite endpoint was cardiovascular death, myocardial infarction, unstable angina, coronary revascularization ≥30 days post randomization, or stroke. The on-treatment analysis included patients who received study drug for the duration of the trial or experienced a primary endpoint or non-cardiovascular death within 30 days of drug discontinuation. Results Mean LDL-C values at 1 year were 71 mg/dL for P/S and 54 mg/dL for Ez/S (absolute difference− 17 mg/dL = −24%; P < .001). The 7-year Kaplan–Meier estimate of the primary endpoint occurred in 32.4% in the P/S arm and 29.8% in the Ez/S arm (absolute difference 2.6%; HRadj 0.92 [95% CI 0.87–0.98]; P = .01). The absolute treatment effect favoring Ez/S was 30% greater than in the intention-to-treat analysis of IMPROVE-IT. Conclusions This analysis provides additional support for the efficacy and safety of adding Ez to S in this high-risk, post-ACS population.
identifier
0ISSN: 0002-8703
1EISSN: 1097-6744
2DOI: 10.1016/j.ahj.2016.09.004
3PMID: 27914504
4CODEN: AHJOA2
languageeng
publisherUnited States: Elsevier Inc
subjectAbridged Index Medicus ; Acute Coronary Syndrome - blood ; Acute Coronary Syndrome - diagnosis ; Acute Coronary Syndrome - drug therapy ; Aged ; Analysis ; Anticholesteremic Agents - administration & dosage ; Anticholesteremic Agents - adverse effects ; Cardiovascular ; Cardiovascular disease ; Cholesterol, LDL - blood ; Clinical trials ; Coronary heart disease ; Dose-Response Relationship, Drug ; Drug Monitoring - methods ; Drug Synergism ; Drug Therapy, Combination - methods ; Drug Therapy, Combination - statistics & numerical data ; Ezetimibe - administration & dosage ; Ezetimibe - adverse effects ; Female ; Health risk assessment ; Humans ; Low density lipoprotein ; Male ; Middle Aged ; Mortality ; Simvastatin ; Simvastatin - administration & dosage ; Simvastatin - adverse effects ; Treatment Outcome
ispartofThe American heart journal, 2016, Vol.182, p.89-96
rights
02016 Elsevier Inc.
1Copyright © 2016 Elsevier Inc. All rights reserved.
2COPYRIGHT 2016 Elsevier B.V.
3Copyright Elsevier Limited Dec 01, 2016
lds50peer_reviewed
citedbyFETCH-LOGICAL-c550t-d42a3b34c7ce87a68e2f1bbaeb87460c62697bbd122b24a158332ec22075095c3
citesFETCH-LOGICAL-c550t-d42a3b34c7ce87a68e2f1bbaeb87460c62697bbd122b24a158332ec22075095c3
links
openurl$$Topenurl_article
openurlfulltext$$Topenurlfull_article
thumbnail$$Usyndetics_thumb_exl
backlink$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27914504$$D View this record in MEDLINE/PubMed
search
creatorcontrib
0Blazing, Michael A., MD
1Giugliano, Robert P., MD, SM
2de Lemos, James A., MD
3Cannon, Christopher P., MD
4Tonkin, Andrew, MBBS, MD
5Ballantyne, Christie M., MD
6Lewis, Basil S., MD
7Musliner, Thomas A., MD
8Tershakovec, Andrew M., MD, MPH
9Lokhnygina, Yuliya, PhD
10White, Jennifer A., MS
11Reist, Craig, PhD
12McCagg, Amy, BS
13Braunwald, Eugene, MD
title
0On-Treatment Analysis of the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT)
1The American heart journal
addtitleAm Heart J
descriptionAbstract Background We aimed to determine the efficacy and safety of adding ezetimibe (Ez) to simvastatin (S) in a post-acute coronary syndrome (ACS) population in a prespecified on-treatment analysis. Methods We evaluated 17,706 post-ACS patients from the IMPROVE-IT trial who had low-density lipoprotein cholesterol (LDL-C) values between 50 and 125 mg/dL and who received Ez 10 mg/day with S 40 mg/day (Ez/S) or placebo with simvastatin 40 mg/day (P/S). The primary composite endpoint was cardiovascular death, myocardial infarction, unstable angina, coronary revascularization ≥30 days post randomization, or stroke. The on-treatment analysis included patients who received study drug for the duration of the trial or experienced a primary endpoint or non-cardiovascular death within 30 days of drug discontinuation. Results Mean LDL-C values at 1 year were 71 mg/dL for P/S and 54 mg/dL for Ez/S (absolute difference− 17 mg/dL = −24%; P < .001). The 7-year Kaplan–Meier estimate of the primary endpoint occurred in 32.4% in the P/S arm and 29.8% in the Ez/S arm (absolute difference 2.6%; HRadj 0.92 [95% CI 0.87–0.98]; P = .01). The absolute treatment effect favoring Ez/S was 30% greater than in the intention-to-treat analysis of IMPROVE-IT. Conclusions This analysis provides additional support for the efficacy and safety of adding Ez to S in this high-risk, post-ACS population.
subject
0Abridged Index Medicus
1Acute Coronary Syndrome - blood
2Acute Coronary Syndrome - diagnosis
3Acute Coronary Syndrome - drug therapy
4Aged
5Analysis
6Anticholesteremic Agents - administration & dosage
7Anticholesteremic Agents - adverse effects
8Cardiovascular
9Cardiovascular disease
10Cholesterol, LDL - blood
11Clinical trials
12Coronary heart disease
13Dose-Response Relationship, Drug
14Drug Monitoring - methods
15Drug Synergism
16Drug Therapy, Combination - methods
17Drug Therapy, Combination - statistics & numerical data
18Ezetimibe - administration & dosage
19Ezetimibe - adverse effects
20Female
21Health risk assessment
22Humans
23Low density lipoprotein
24Male
25Middle Aged
26Mortality
27Simvastatin
28Simvastatin - administration & dosage
29Simvastatin - adverse effects
30Treatment Outcome
issn
00002-8703
11097-6744
fulltexttrue
rsrctypearticle
creationdate2016
recordtypearticle
recordideNqNkl2L1DAYhYso7jj6A7yRgjfrRWuSpkmrIAzLqAMrI-u4tyFN37oZ22RM0oX596aOuuuwLBJI2uQ5583HSZLnGOUYYfZ6m8urbU7iZ47qHCH6IJlhVPOMcUofJjOEEMkqjoqT5In32_jLSMUeJyeE15iWiM4SszbZxoEMA5iQLozs91771HZpuIJ0NeycvYY2vYB2VEFbM62sx6DsAP5NerkP1mmTLrtOK6n26coEcEZOpOzTjdOxP119-nyxvlxmq82rp8mjTvYenv0e58nX98vN2cfsfP1hdbY4z1RZopC1lMiiKajiCiouWQWkw00joak4ZUgxwmreNC0mpCFU4rIqCgKKEMRLVJeqmCenB9-4_x8j-CAG7RX0vTRgRy9wxaqCohqV_4HGioTiuojoyyN0a8d43P5A8aJk5Bb1TfYgtOlscFJNpmJBOasZxbH4PMnvoGJrYdDKGuh0nP9H8OIOgbgN4AOgnPXeQSd2Tg_S7QVGYsqL2IqYFzHlRaBaxLzcmO7GZoD2r-JPQCLAj0yVDr_eN1bX_b3Wbw9KiO98rcEJrzQYBa12oIJorb5X_e5IrXptYsj677AHf3PvwhOBxJcp6lPSMSsQruuy-AlyTvHu
startdate2016
enddate2016
creator
0Blazing, Michael A., MD
1Giugliano, Robert P., MD, SM
2de Lemos, James A., MD
3Cannon, Christopher P., MD
4Tonkin, Andrew, MBBS, MD
5Ballantyne, Christie M., MD
6Lewis, Basil S., MD
7Musliner, Thomas A., MD
8Tershakovec, Andrew M., MD, MPH
9Lokhnygina, Yuliya, PhD
10White, Jennifer A., MS
11Reist, Craig, PhD
12McCagg, Amy, BS
13Braunwald, Eugene, MD
general
0Elsevier Inc
1Elsevier B.V
2Elsevier Limited
scope
0CGR
1CUY
2CVF
3ECM
4EIF
5NPM
6AAYXX
7CITATION
8BKMMT
9BSHEE
103V.
117QO
127RV
137TS
147X7
157XB
1688C
1788E
188AO
198C1
208FD
218FI
228FJ
238FK
248G5
25ABUWG
26AN0
27AZQEC
28BENPR
29DWQXO
30FR3
31FYUFA
32GHDGH
33GNUQQ
34GUQSH
35K9.
36KB0
37M0S
38M0T
39M1P
40M2O
41MBDVC
42NAPCQ
43P64
44PADUT
45PQEST
46PQQKQ
47PQUKI
48PRINS
49Q9U
507X8
sort
creationdate2016
titleOn-Treatment Analysis of the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT)
authorBlazing, Michael A., MD ; Giugliano, Robert P., MD, SM ; de Lemos, James A., MD ; Cannon, Christopher P., MD ; Tonkin, Andrew, MBBS, MD ; Ballantyne, Christie M., MD ; Lewis, Basil S., MD ; Musliner, Thomas A., MD ; Tershakovec, Andrew M., MD, MPH ; Lokhnygina, Yuliya, PhD ; White, Jennifer A., MS ; Reist, Craig, PhD ; McCagg, Amy, BS ; Braunwald, Eugene, MD
facets
frbrtype5
frbrgroupidcdi_FETCH-LOGICAL-c550t-d42a3b34c7ce87a68e2f1bbaeb87460c62697bbd122b24a158332ec22075095c3
rsrctypearticles
prefilterarticles
languageeng
creationdate2016
topic
0Abridged Index Medicus
1Acute Coronary Syndrome - blood
2Acute Coronary Syndrome - diagnosis
3Acute Coronary Syndrome - drug therapy
4Aged
5Analysis
6Anticholesteremic Agents - administration & dosage
7Anticholesteremic Agents - adverse effects
8Cardiovascular
9Cardiovascular disease
10Cholesterol, LDL - blood
11Clinical trials
12Coronary heart disease
13Dose-Response Relationship, Drug
14Drug Monitoring - methods
15Drug Synergism
16Drug Therapy, Combination - methods
17Drug Therapy, Combination - statistics & numerical data
18Ezetimibe - administration & dosage
19Ezetimibe - adverse effects
20Female
21Health risk assessment
22Humans
23Low density lipoprotein
24Male
25Middle Aged
26Mortality
27Simvastatin
28Simvastatin - administration & dosage
29Simvastatin - adverse effects
30Treatment Outcome
toplevel
0peer_reviewed
1online_resources
creatorcontrib
0Blazing, Michael A., MD
1Giugliano, Robert P., MD, SM
2de Lemos, James A., MD
3Cannon, Christopher P., MD
4Tonkin, Andrew, MBBS, MD
5Ballantyne, Christie M., MD
6Lewis, Basil S., MD
7Musliner, Thomas A., MD
8Tershakovec, Andrew M., MD, MPH
9Lokhnygina, Yuliya, PhD
10White, Jennifer A., MS
11Reist, Craig, PhD
12McCagg, Amy, BS
13Braunwald, Eugene, MD
collection
0Medline
1MEDLINE
2MEDLINE (Ovid)
3MEDLINE
4MEDLINE
5PubMed
6CrossRef
7Gale General OneFile (A&I only)
8Academic OneFile (A&I only)
9ProQuest Central (Corporate)
10Biotechnology Research Abstracts
11Nursing & Allied Health Database
12Physical Education Index
13Health & Medical Collection
14ProQuest Central (purchase pre-March 2016)
15Healthcare Administration Database (Alumni)
16Medical Database (Alumni Edition)
17ProQuest Pharma Collection
18Public Health Database
19Technology Research Database
20Hospital Premium Collection
21Hospital Premium Collection (Alumni Edition)
22ProQuest Central (Alumni) (purchase pre-March 2016)
23Research Library (Alumni Edition)
24ProQuest Central (Alumni Edition)
25British Nursing Database
26ProQuest Central Essentials
27ProQuest Central
28ProQuest Central Korea
29Engineering Research Database
30Health Research Premium Collection
31Health Research Premium Collection (Alumni)
32ProQuest Central Student
33Research Library Prep
34ProQuest Health & Medical Complete (Alumni)
35Nursing & Allied Health Database (Alumni Edition)
36Health & Medical Collection (Alumni Edition)
37Healthcare Administration Database
38Medical Database
39Research Library
40Research Library (Corporate)
41Nursing & Allied Health Premium
42Biotechnology and BioEngineering Abstracts
43Research Library China
44ProQuest One Academic Eastern Edition
45ProQuest One Academic
46ProQuest One Academic UKI Edition
47ProQuest Central China
48ProQuest Central Basic
49MEDLINE - Academic
jtitleThe American heart journal
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
au
0Blazing, Michael A., MD
1Giugliano, Robert P., MD, SM
2de Lemos, James A., MD
3Cannon, Christopher P., MD
4Tonkin, Andrew, MBBS, MD
5Ballantyne, Christie M., MD
6Lewis, Basil S., MD
7Musliner, Thomas A., MD
8Tershakovec, Andrew M., MD, MPH
9Lokhnygina, Yuliya, PhD
10White, Jennifer A., MS
11Reist, Craig, PhD
12McCagg, Amy, BS
13Braunwald, Eugene, MD
formatjournal
genrearticle
ristypeJOUR
atitleOn-Treatment Analysis of the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT)
jtitleThe American heart journal
addtitleAm Heart J
date2016
risdate2016
volume182
spage89
epage96
pages89-96
issn0002-8703
eissn1097-6744
codenAHJOA2
abstractAbstract Background We aimed to determine the efficacy and safety of adding ezetimibe (Ez) to simvastatin (S) in a post-acute coronary syndrome (ACS) population in a prespecified on-treatment analysis. Methods We evaluated 17,706 post-ACS patients from the IMPROVE-IT trial who had low-density lipoprotein cholesterol (LDL-C) values between 50 and 125 mg/dL and who received Ez 10 mg/day with S 40 mg/day (Ez/S) or placebo with simvastatin 40 mg/day (P/S). The primary composite endpoint was cardiovascular death, myocardial infarction, unstable angina, coronary revascularization ≥30 days post randomization, or stroke. The on-treatment analysis included patients who received study drug for the duration of the trial or experienced a primary endpoint or non-cardiovascular death within 30 days of drug discontinuation. Results Mean LDL-C values at 1 year were 71 mg/dL for P/S and 54 mg/dL for Ez/S (absolute difference− 17 mg/dL = −24%; P < .001). The 7-year Kaplan–Meier estimate of the primary endpoint occurred in 32.4% in the P/S arm and 29.8% in the Ez/S arm (absolute difference 2.6%; HRadj 0.92 [95% CI 0.87–0.98]; P = .01). The absolute treatment effect favoring Ez/S was 30% greater than in the intention-to-treat analysis of IMPROVE-IT. Conclusions This analysis provides additional support for the efficacy and safety of adding Ez to S in this high-risk, post-ACS population.
copUnited States
pubElsevier Inc
pmid27914504
doi10.1016/j.ahj.2016.09.004